CIRM extends retinal disease research grant.
NEW YORK, N.Y., April 09, 2015-The California Institute of Regenerative Medicine, the state's stem cell funding agency, has extended NeoStem, Inc.'s (NBS) study under a 2014 Early Translational grant from for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa.
Under the $4 million grant made to the University of California, Irvine, NeoStem is entitled, through a sub-award, to $1 million of new funds adding to the original $500,000 awarded. The goals of the research are to generate three-dimensional retinal tissue, to investigate the ability of adult induced pluripotent stem cells to restore sight in rodent models of retinal degeneration and to make eventual preparations for clinical use of the tissue.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||News Briefs|
|Publication:||Stem Cell Lab World|
|Date:||Apr 20, 2015|
|Previous Article:||Medidata technology platform broadened for better clinical trials.|
|Next Article:||Company disparages investor class action lawsuit.|